Гепатит В

Список литературы

Основные статьи

Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Полный текст  Аннотация

European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98.Полный текст  Аннотация

Статьи, указанные как источники

1. Chu CJ, Keeffe EB, Han SH, et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 2003 Aug;125(2):444-51. Аннотация

2. Mohanty SR, Kupfer SS, Khiani V. Treatment of chronic hepatitis B. Nat Clin Pract Gastroenterol Hepatol. 2006 Aug;3(8):446-58. Аннотация

3. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Полный текст  Аннотация

4. Chu CJ, Lok AS. Clinical significance of hepatitis B virus genotypes. Hepatology. 2002 May;35(5):1274-6.Полный текст  Аннотация

5. Erhardt A, Blondin D, Hauck K, et al. Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005 Jul;54(7):1009-13.Полный текст  Аннотация

6. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet. 2005 Jan 8-14;365(9454):123-9. Аннотация

7. Kao JH, Wu NH, Chen PJ, et al. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 2000 Dec;33(6):998-1002. Аннотация

8. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med. 2005 Jun 30;352(26):2682-95. Аннотация

9. World Health Organization. Hepatitis B: fact sheet. July 2019 [internet publication].Полный текст

10. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions. Gastroenterology. 2017 May;152(6):1297-1309.Полный текст  Аннотация

11. Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis B virus infection in children and adolescents. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-76. Аннотация

12. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol. 2003;39 Suppl 1:S64-9. Аннотация

13. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat. 2006 Dec;13(12):787-98. Аннотация

14. Centers for Disease Control and Prevention. Surveillance for viral hepatitis – United States, 2017. September 2019 [internet publication].Полный текст

15. Public Health England. Acute hepatitis B (England): annual report for 2018. April 2020 [internet publication].Полный текст

16. Hu KQ. Hepatitis B virus (HBV) infection in Asian and Pacific Islander Americans (APIAs): how can we do better for this special population? Am J Gastroenterol. 2008 Jul;103(7):1824-33. Аннотация

17. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997 Dec 11;337(24):1733-45. Аннотация

18. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004 Mar 11;350(11):1118-29. Аннотация

19. Guidotti LG, Rochford R, Chung J, et al. Viral clearance without destruction of infected cells during acute HBV infection. Science. 1999 Apr 30;284(5415):825-9. Аннотация

20. Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996 Jan;4(1):25-36. Аннотация

21. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 1995;13:29-60. Аннотация

22. Tuttleman JS, Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell. 1986 Nov 7;47(3):451-60. Аннотация

23. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000 Mar;64(1):51-68.Полный текст  Аннотация

24. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science. 1986 Apr 25;232(4749):477-84. Аннотация

25. Newbold JE, Xin H, Tencza M, et al. The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol. 1995 Jun;69(6):3350-7.Полный текст  Аннотация

26. Zoulim F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J Hepatol. 2005 Mar;42(3):302-8. Аннотация

27. Yuen MF, Wong DK, Sum SS, et al. Effect of lamivudine therapy on the serum covalently closed-circular (ccc) DNA of chronic hepatitis B infection. Am J Gastroenterol. 2005 May;100(5):1099-103. Аннотация

28. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology. 2006 Sep;44(3):675-84. Аннотация

29. Wong DK, Yuen MF, Ngai VW, et al. One-year entecavir or lamivudine therapy results in reduction of hepatitis B virus intrahepatic covalently closed circular DNA levels. Antivir Ther. 2006;11(7):909-16. Аннотация

30. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004 Jun;126(7):1750-8. Аннотация

31. Sung JJ, Wong ML, Bowden S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy. Gastroenterology. 2005 Jun;128(7):1890-7. Аннотация

32. Bourne EJ, Dienstag JL, Lopez VA, et al. Quantitative analysis of HBV cccDNA from clinical specimens: correlation with clinical and virological response during antiviral therapy. J Viral Hepat. 2007 Jan;14(1):55-63. Аннотация

33. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98.Полный текст  Аннотация

34. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008 Apr;23(4):512-20.Полный текст  Аннотация

35. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer. 1998 Jan 30;75(3):347-54.Полный текст  Аннотация

36. Jamma S, Hussain G, Lau DT. Current concepts of HBV/HCV coinfection: coexistence, but not necessarily in harmony. Curr Hepat Rep. 2010;9(4):260-9.Полный текст  Аннотация

37. Bellecave P, Gouttenoire J, Gajer M, et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology. 2009 Jul;50(1):46-55.Полный текст  Аннотация

38. Ghendon Y. Perinatal transmission of hepatitis B virus in high-incidence countries. J Virol Methods. 1987 Aug;17(1-2):69-79. Аннотация

39. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis. 2002 Mar 15;185(6):713-9. Аннотация

40. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017 Dec;5(12):e1192-e1207.Полный текст  Аннотация

41. Wasley A, Miller JT, Finelli L. Surveillance for acute viral hepatitis: United States, 2005. MMWR Surveill Summ. 2007 Mar 16;56(3):1-24. Аннотация

42. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015 [internet publication].Полный текст

43. Thio CL. Hepatitis B in the human immunodeficiency virus-infected patient: epidemiology, natural history, and treatment. Semin Liver Dis. 2003 May;23(2):125-36. Аннотация

44. Strader DB. Understudied populations with hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S226-36. Аннотация

45. Chen G, Wang C, Chen J, et al. Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology. 2017 Jul;66(1):13-26.Полный текст  Аннотация

46. Mücke MM, Backus LI, Mücke VT, et al. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2018 Mar;3(3):172-80. Аннотация

47. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion. 2002 Aug;42(8):975-9. Аннотация

48. Mahoney FJ, Stewart K, Hu H, et al. Progress toward the elimination of hepatitis B virus transmission among health care workers in the United States. Arch Intern Med. 1997 Dec 8-22;157(22):2601-5. Аннотация

49. Harpaz R, Von Seidlein L, Averhoff FM, et al. Transmission of hepatitis B virus to multiple patients from a surgeon without evidence of inadequate infection control. N Engl J Med. 1996 Feb 29;334(9):549-54. Аннотация

50. Lettau LA, Smith JD, Williams D, et al. Transmission of hepatitis B with resultant restriction of surgical practice. JAMA. 1986 Feb 21;255(7):934-7. Аннотация

51. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981 Mar 7;1(8219):550-1. Аннотация

52. Davis LG, Weber DJ, Lemon SM. Horizontal transmission of hepatitis B virus. Lancet. 1989 Apr 22;1(8643):889-93. Аннотация

53. Falla AM, Hofstraat SHI, Duffell E, et al. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018 Feb 12;18(1):79.Полный текст  Аннотация

54. Cendoroglo Neto M, Draibe SA, Silva AE, et al. Incidence of and risk factors for hepatitis B virus and hepatitis C virus infection among hemodialysis and CAPD patients: evidence for environmental transmission. Nephrol Dial Transplant. 1995;10(2):240-6. Аннотация

55. Robinson CL, Bernstein H, Poehling K, et al. Advisory Committee on Immunization Practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):130-2.Полный текст  Аннотация

56. Public Health England. Hepatitis B: the green book, chapter 18. June 2017 [internet publication].Полный текст

57. Kim DK, Hunter P. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2019. MMWR Morb Mortal Wkly Rep. 2019 Feb 8;68(5):115-18.Полный текст  Аннотация

58. Freedman MS, Hunter P, Ault K, et al. Advisory Committee on Immunization Practices recommended immunization schedule for adults aged 19 years or older - United States, 2020. MMWR Morb Mortal Wkly Rep. 2020 Feb 7;69(5):133-5.Полный текст  Аннотация

59. Schillie S, Harris A, Link-Gelles R, et al. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep. 2018 Apr 20;67(15):455-58.Полный текст  Аннотация

60. Pham H, Geraci SA, Burton MJ, et al. Adult immunizations: update on recommendations. Am J Med. 2011 Aug;124(8):698-701. Аннотация

61. Makris MC, Polyzos KA, Mavros MN, et al. Safety of hepatitis B, pneumococcal polysaccharide and meningococcal polysaccharide vaccines in pregnancy: a systematic review. Drug Saf. 2012 Jan 1;35(1):1-14. Аннотация

62. Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011 Dec 23;60(50):1709-11.Полный текст  Аннотация

63. Fabrizi F, Dixit V, Martin P, et al. Meta-analysis: the impact of diabetes mellitus on the immunological response to hepatitis B virus vaccine in dialysis patients. Aliment Pharmacol Ther. 2011 Apr;33(7):815-21. Аннотация

64. Fabrizi F, Dixit V, Martin P, et al. Hepatitis C virus and the immunological response to hepatitis B virus vaccine in dialysis patients: meta-analysis of clinical studies. J Viral Hepat. 2011 Dec;18(12):871-6. Аннотация

65. Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009 Jun;3(2):47-91. Аннотация

66. Jiang HY, Wang SY, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. Vaccine. 2017 May 9;35(20):2633-41. Аннотация

67. Aggeletopoulou I, Davoulou P, Konstantakis C, et al. Response to hepatitis B vaccination in patients with liver cirrhosis. Rev Med Virol. 2017 Nov;27(6). Аннотация

68. Liang TJ. Hepatitis B: the virus and disease. Hepatology. 2009 May;49(5 suppl):S13-21.Полный текст  Аннотация

69. McMahon BJ, Alward WL, Hall DB, et al. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985 Apr;151(4):599-603. Аннотация

70. Abara WE, Qaseem A, Schillie S, et al; High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.Полный текст  Аннотация

71. Lok AS, Liang RH, Chiu EK, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991 Jan;100(1):182-8.Полный текст  Аннотация

72. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. Ann Rheum Dis. 2003 Jul;62(7):686-7.Полный текст  Аннотация

73. Amini A, Varsaneux O, Kelly H, et al. Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis. BMC Infect Dis. 2017 Nov 1;17(suppl 1):698.Полный текст  Аннотация

74. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010 Oct;139(4):1230-7.Полный текст  Аннотация

75. Cardoso AC, Carvalho-Filho RJ, Marcellin P. Transient elastography in chronic viral hepatitis: a critical appraisal. Gut. 2011 Jun;60(6):759-64. Аннотация

76. Cardoso AC, Carvalho-Filho RJ, Stern C, et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012 Apr;32(4):612-21. Аннотация

77. Castéra L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepatol. 2009 May;16(5):300-14. Аннотация

78. Castéra L, Bernard PH, Le Bail P, et al. Transient elastography and biomarkers for liver fibrosis assessment and follow-up of inactive hepatitis B carriers. Aliment Pharmacol Ther. 2011 Feb;33(4):455-65.Полный текст  Аннотация

79. Fraquelli M, Branchi F. The role of transient elastography in patients with hepatitis B viral disease. Dig Liver Dis. 2011 Jan;43 Suppl 1:S25-31. Аннотация

80. Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009 Feb;29(2):242-7. Аннотация

81. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40.Полный текст  Аннотация

82. Yin Z, Zou J, Li Q, et al. Diagnostic value of FIB-4 for liver fibrosis in patients with hepatitis B: a meta-analysis of diagnostic test. Oncotarget. 2017 Apr 4;8(14):22944-53.Полный текст  Аннотация

83. Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology. 2008 Feb;47(2):380-4.Полный текст  Аннотация

84. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol. 2011 Apr;54(4):650-9. Аннотация

85. Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: A systematic review and meta-analysis. PLoS One. 2017 Nov 6;12(11):e0186660.Полный текст  Аннотация

86. Centers for Disease Control and Prevention. Public Health Service inter-agency guidelines for screening donors of blood, plasma, organs, tissues, and semen for evidence of hepatitis B and hepatitis C. MMWR Recomm Rep. 1991 Apr 19;40(RR-4):1-17. Аннотация

87. Saldanha J, Gerlich W, Lelie N, et al; WHO Collaborative Study Group. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang. 2001 Jan;80(1):63-71. Аннотация

88. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006 Mar;101(3):513-23. Аннотация

89. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50. Аннотация

90. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003 Mar-Apr;23(2C):1747-53. Аннотация

91. US Preventive Services Task Force. Hepatitis B virus infection in nonpregnant adolescents and adults: screening. May 2020 [internet publication].Полный текст

92. US Preventive Services Task Force., Owens DK, Davidson KW, et al. Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement. JAMA. 2019 Jul 23;322(4):349-54.Полный текст  Аннотация

93. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol. 2020 Jul 27 [Epub ahead of print].Полный текст  Аннотация

94. Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E, et al. Pharmacological interventions for acute hepatitis B infection: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017 Mar 21;(3):CD011645.Полный текст  Аннотация

95. Papatheodoridis GV, Lampertico P, Manolakopoulos S, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol. 2010 Aug;53(2):348-56. Аннотация

96. Wong GL, Yiu KK, Wong VW, et al. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther. 2010 Nov;32(9):1059-68.Полный текст  Аннотация

97. Sung JJ, Tsoi KK, Wong VW, et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther. 2008 Nov 1;28(9):1067-77. Аннотация

98. Miyake Y, Kobashi H, Yamamoto K. Meta-analysis: the effect of interferon on development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol. 2009;44(5):470-5. Аннотация

99. Tang LSY, Covert E, Wilson E, et al. Chronic hepatitis B infection: a review. JAMA. 2018 May 1;319(17):1802-13. Аннотация

100. Lampertico P, Buti M, Fung S, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. Lancet Gastroenterol Hepatol. 2020 May;5(5):441-53. Аннотация

101. Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2007 Nov;133(5):1437-44. Аннотация

102. Teng YX, Li MJ, Xiang BD, et al. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Gut. 2020 Oct;69(10):1900-2.Полный текст  Аннотация

103. Yip TC, Wong VW, Chan HL, et al. Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China. Gastroenterology. 2020 Jan;158(1):215-225.e6.Полный текст  Аннотация

104. Choi J, Kim HJ, Lee J, et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. JAMA Oncol. 2019 Jan 1;5(1):30-6.Полный текст  Аннотация

105. Tseng CH, Hsu YC, Chen TH, et al. Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Sep 29 [Epub ahead of print]. Аннотация

106. Carosi G, Rizzetto M, Alberti A, et al. Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. Dig Liver Dis. 2011 Apr;43(4):259-65. Аннотация

107. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004 Oct 7;351(15):1521-31.Полный текст  Аннотация

108. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology. 2005 Jul;42(1):121-9.Полный текст  Аннотация

109. Chang TT, Liaw YF, Wu SS, et a. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology. 2010 Sep;52(3):886-93.Полный текст  Аннотация

110. Buster EH, Hansen BE, Buti M, et al; HBV 99-01 Study Group. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology. 2007 Aug;46(2):388-94.Полный текст  Аннотация

111. Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology. 1995 Sep;109(3):908-16. Аннотация

112. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology. 2009 Dec;50(6):2001-6.Полный текст  Аннотация

113. Altfeld M, Rockstroh JK, Addo M, et al. Reactivation of hepatitis B in a long-term anti-HBs-positive patient with AIDS following lamivudine withdrawal. J Hepatol. 1998 Aug;29(2):306-9. Аннотация

114. Jiang XW, Ye JZ, Li YT, et al. Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis. World J Gastroenterol. 2018 Jul 28;24(28):3181-91.Полный текст  Аннотация

115. Yurdaydın C, Idilman R, Bozkaya H, et al. Natural history and treatment of chronic delta hepatitis. J Viral Hepat. 2010 Nov;17(11):749-56. Аннотация

116. Funk AL, Lu Y, Yoshida K, et al. Efficacy and safety of antiviral prophylaxis during pregnancy to prevent mother-to-child transmission of hepatitis B virus: a systematic review and meta-analysis. Lancet Infect Dis. 2020 Aug 14 [Epub ahead of print].Полный текст  Аннотация

117. Hyun MH, Lee YS, Kim JH, et al. Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther. 2017 Jun;45(12):1493-505. Аннотация

118. Li W, Jia L, Zhao X, et al. Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: a meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol. 2018 Aug 2;18(1):121.Полный текст  Аннотация

119. Tavakolpour S, Darvishi M, Mirsafaei HS, et al. Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B infection during pregnancy: a systematic review. Infect Dis (Lond). 2017 Oct 11;50(2):95-106. Аннотация

120. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol. 2011 Dec;55(6):1215-21. Аннотация

121. Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: systematic review and meta-analysis. Obstet Gynecol. 2010 Jul;116(1):147-59. Аннотация

122. Su GG, Pan KH, Zhao NF, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol. 2004 Mar 15;10(6):910-2. Аннотация

123. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat. 2003 Jul;10(4):294-7. Аннотация

124. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat. 2009 Feb;16(2):94-103. Аннотация

125. Shi Z, Yang Y, Wang H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus: a meta-analysis and systematic review. Arch Pediatr Adolesc Med. 2011 Sep;165(9):837-46. Аннотация

126. Alonso S, Guerra AR, Carreira L, et al. Upcoming pharmacological developments in chronic hepatitis B: can we glimpse a cure on the horizon? BMC Gastroenterol. 2017 Dec 21;17(1):168.Полный текст  Аннотация

127. Bloom K, Maepa MB, Ely A, et al. Gene therapy for chronic HBV-can we eliminate cccDNA? Genes (Basel). 2018 Apr 12;9(4).Полный текст  Аннотация

128. Soriano V, Sherman KE, Barreiro P. Hepatitis delta and HIV infection. AIDS. 2017 Apr 24;31(7):875-84. Аннотация

129. Wang Y, Xiong J, Niu M, et al. Statins and the risk of cirrhosis in hepatitis B or C patients: a systematic review and dose-response meta-analysis of observational studies. Oncotarget. 2017 Jul 27;8(35):59666-76.Полный текст  Аннотация

130. Simon TG, Duberg AS, Aleman S, et al. Lipophilic Statins and Risk for Hepatocellular Carcinoma and Death in Patients With Chronic Viral Hepatitis: Results From a Nationwide Swedish Population. Ann Intern Med. 2019 Sep 3;171(5):318-27.Полный текст  Аннотация

131. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med. 1996 May 30;334(22):1422-7. Аннотация

132. Gish RG, Chang TT, Lai CL, et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010 Jan;17(1):16-22. Аннотация

133. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006 Feb;43(2 Suppl 1):S173-81. Аннотация

134. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May;142(6):1264-73.e1.Полный текст  Аннотация

135. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005 May;9(2):191-211, v. Аннотация

136. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002 Jul 18;347(3):168-74. Аннотация

137. Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006 Mar;130(3):678-86. Аннотация

138. Kuang XJ, Jia RR, Huo RR, et al. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance. J Viral Hepat. 2018 May 2;25(9):1026-37. Аннотация

139. Shi Y, Zheng M. Hepatitis B virus persistence and reactivation. BMJ. 2020 Sep 1;370:m2200.Полный текст  Аннотация

140. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982 Oct 30;2(8305):945-7. Аннотация

141. Feray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology. 1993 Feb;104(2):549-55. Аннотация

142. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther. 2006 Sep 1;24(5):781-8. Аннотация

143. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007 Feb;45(2):507-39.Полный текст  Аннотация

144. Buti M, Wong DK, Gane E, et al. Safety and efficacy of stopping tenofovir disoproxil fumarate in patients with chronic hepatitis B following at least 8 years of therapy: a prespecified follow-up analysis of two randomised trials. Lancet Gastroenterol Hepatol. 2019 Apr;4(4):296-304. Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности